Phase
Condition
Platelet Disorders
Leukemia
Acute Myeloid Leukemia
Treatment
Fludarabine
Cytarabine
Clinical Study ID
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Clinical and laboratory diagnosis of CBF-AML,including RUNX1-RUNX1T1 and CBF-MYH11fusion gene rearrangement by PCR/FISH
In status of complete remission after one to two courses of induction therapy
Total bilirubinic acid ≤ 35μmol/L, AST/ALT<2 times abnormal level, serum creatinine < 1.5mg/ml
Cardiac function: EF ≥ 50%
Hydroxyurea can be used for patient with white blood cell count ≥ 50*109/L
ECOG (Eastern Cooperative Oncology Group) score: ≤ 2
Exclusion
Exclusion Criteria:
Relapsed/refractory AML
Serious liver/ kidney dysfunction
Cardiac function level: 2 above
Female in pregnancy or lactation
With serious infection diseases or other diseases
Not obey the principle of clinical study
Study Design
Study Description
Connect with a study center
Xianmin Song
Shanghai, Shanghai 200080
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.